Methods and compositions for treating cannabinoid overdose with a cannabinoid receptor antagonist

Abstract

Disclosed herein are formulations and methods for reversing one or more symptoms of cannabinoid overdose, comprising parenterally administering a CB1 antagonist in an amount sufficient to reverse the cannabinoid overdose symptoms.

What is claimed is: 
     
         1 . A composition formulated for parenteral administration comprising an amount of drinabant or a salt or polymorph thereof effective to reverse cannabinoid overdose or one or more symptoms thereof in a subject. 
     
     
         2 . The composition as recited in  claim 1 , further comprising at least one agent that acts as a non-ionic solubilizer and/or emulsifying agent. 
     
     
         3 . A method of treating, reversing, or reducing cannabinoid overdose or one or more symptoms thereof in a subject, comprising parenterally administering to the subject an amount of drinabant or a salt or polymorph thereof, effective to treat, reverse, or reduce cannabinoid overdose or one or more symptoms thereof. 
     
     
         4 . The method as recited in  claim 3 , wherein the plasma concentrations achieved by parenteral administration of drinabant or a salt or polymorph thereof sufficient to treat, reverse, or reduce cannabinoid overdose or one or more symptoms thereof is between about 200 ng/mL to about 730 ng/mL. 
     
     
         5 . The method as recited in  claim 4 , wherein the parenteral route of administration is chosen from among intravenous (IV), intramuscular (IM), and subcutaneous (SC). 
     
     
         6 . The method as recited in  claim 5 , wherein the parenteral route of administration is IV. 
     
     
         7 . The method as recited in  claim 6 , wherein the IV dose is delivered by IV injection. 
     
     
         8 . The method as recited in  claim 7 , wherein the IV dose is delivered in a liquid volume of between about 1 mL and about 20 mL. 
     
     
         9 . The method of  claim 6 , wherein the IV dose is delivered by IV infusion. 
     
     
         10 . The method as recited in  claim 9 , wherein the IV infusion is delivered in a liquid volume of between about 50 mL to about 500 mL. 
     
     
         11 . The method as recited in  claim 9 , wherein the IV infusion is delivered over a period of about 30 minutes to about 2 hours. 
     
     
         12 . The method as recited in  claim 9 , wherein the IV infusion is delivered at a rate of about 0.5 mL/minute to about 2 mL/minute. 
     
     
         13 . The method as recited in  claim 9 , wherein the onset of reversal of symptom(s) of cannabinoid overdose is apparent within 30 minutes to about 60 minutes. 
     
     
         14 . The method as recited in  claim 5 , wherein the parenteral route of administration is IM or SC. 
     
     
         15 . The method as recited in  claim 14 , wherein the amount of drinabant, or a salt or polymorph thereof sufficient to reverse the cannabinoid overdose symptom(s) is between about 5 mg and about 100 mg per IM dose. 
     
     
         16 . The method as recited in  claim 14 , wherein the SC dose is delivered in a liquid volume of between about 1 mL and about 1.5 mL. 
     
     
         17 . The method as recited in  claim 3 , wherein if no response is observed within about 30 minutes to about 2 hours of a first administration of drinabant, and the presence of cannabinoids is confirmed or strongly suspected, a second dose may be administered.